levofloxacin 500mg tablets
waymade healthcare plc - levofloxacin hemihydrate - oral tablet - 500mg
levofloxacin 500mg tablets
de pharmaceuticals - levofloxacin hemihydrate - oral tablet - 500mg
levofloxacin 500mg tablets
mawdsley-brooks & company ltd - levofloxacin hemihydrate - oral tablet - 500mg
levofloxacin injection, solution
zydus pharmaceuticals usa inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 25 mg in 1 ml - levofloxacin injection is indicated for the treatment of adults (> 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin injection is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin injection is indicated for the treatment of community-acquired pneumonia due to methicillin
levofloxacin krka 250 mg film-coated tablets
krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin - pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones, - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections
levofloxacin krka 500 mg film-coated tablets
krka, d.d., novo mesto - levofloxacin hemihydrate - film-coated tablet - 500 milligram(s) - fluoroquinolones; levofloxacin - quinolone antibacterials, fluoroquinolones - it is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): - acute bacterial sinusitis. - acute exacerbations of chronic bronchitis. - community-acquired pneumonia. - complicated skin and soft tissue infections
levofloxacin- levofloxacin tablet, film coated
american health packaging - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus , pseudomonas aeruginosa , serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae , or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies ( 14.1)]. levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, kle
levofloxacin 500mg tablets
alliance healthcare (distribution) ltd - levofloxacin hemihydrate - oral tablet - 500mg
levofloxacin 500mg tablets
a a h pharmaceuticals ltd - levofloxacin hemihydrate - oral tablet - 500mg
levofloxacin 500mg tablets
dr reddy's laboratories (uk) ltd - levofloxacin hemihydrate - oral tablet - 500mg